Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Multicenter cohort findings indicate that early surgery in patients on direct oral anticoagulants was associated with shorter hospitalization without increased bleeding.
Investigators find that short sleep, insomnia, and night shift work are associated with increased risk of knee and hip osteoarthritis and joint replacement.